Bendamustine, Lenalidomide (Revlimid®) and Dexamethasone (BRd) as 2nd-line Therapy for Patients With Relapsed or Refractory Multiple Myeloma (BRd)

This study has been completed.
Sponsor:
Collaborators:
Celgene Corporation
Mundipharma Research GmbH & Co KG
Mundipharma Medical Company
Amgen
Information provided by (Responsible Party):
PD Dr. Ulrich Mey, Kantonsspital Graubünden
ClinicalTrials.gov Identifier:
NCT01701076
First received: September 27, 2012
Last updated: August 23, 2016
Last verified: August 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: February 2016
  Primary Completion Date: February 2016 (Final data collection date for primary outcome measure)